Delivery of anti-migraine compounds through an inhalation route

A method of producing a drug selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene and lisuride in an aerosol form comprising:

• a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

A condensation aerosol for delivery of lidocaine, wherein the condensation aerosol is formed by heating a thin layer containing lidocaine, on a solid support, to produce a vapor of lidocaine, and condensing the vapor to form a condensation aerosol characterized by less than 5% lidocaine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

A condensation aerosol for delivery of verapamil, wherein the condensation aerosol is formed by heating a thin layer containing verapamil, on a solid support, to produce a vapor of verapamil, and condensing the vapor to form a condensation aerosol characterized by less than 5% verapamil degradation products by weight, and an MMAD of about 0.2 to 3 microns.

A condensation aerosol for delivery of diltiazem, wherein the condensation aerosol is formed by heating a thin layer containing diltiazem, on a solid support, to produce a vapor of diltiazem, and condensing the vapor to form a condensation aerosol characterized by less than 5% diltiazem degradation products by weight, and an MMAD of about 0.2 to 3 microns.

A condensation aerosol for delivery of isometheptene, wherein the condensation aerosol is formed by heating a thin layer containing isometheptene, on a solid support, to produce a vapor of isometheptene, and condensing the vapor to form a condensation aerosol characterized by less than 5% isometheptene degradation products by weight, and an MMAD of about 0.2 to 3 microns.

A condensation aerosol for delivery of lisuride, wherein the condensation aerosol is formed by heating a thin layer containing lisuride, on a solid support, to produce a vapor of lisuride, and condensing the vapor to form a condensation aerosol characterized by less than 5% lisuride degradation products by weight, and an MMAD of about 0.2 to 3 microns.

A method of producing lidocaine in an aerosol form comprising:

• a. heating a thin layer containing lidocaine, on a solid support, to produce a vapor of lidocaine, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% lidocaine degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

A method of producing verapamil in an aerosol form comprising:

• a. heating a thin layer containing verapamil, on a solid support, to produce a vapor of verapamil, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% verapamil degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

A method of producing diltiazem in an aerosol form comprising:

• a. heating a thin layer containing diltiazem, on a solid support, to produce a vapor of diltiazem, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% diltiazem degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

A method of producing isometheptene in an aerosol form comprising:

• a. heating a thin layer containing isometheptene, on a solid support, to produce a vapor of isometheptene, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% isometheptene degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

A method of producing lisuride in an aerosol form comprising:

• a. heating a thin layer containing lisuride, on a solid support, to produce a vapor of lisuride, and
• b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% lisuride degradation products by weight, and an MMAD of about 0.2 to about 3 microns.